E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10003658 |
E.1.2 | Term | Atrial fibrillation |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057613 |
E.1.2 | Term | Thromboembolic stroke |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine if apixaban is noninferior to warfarin (INR target range 2.0-3.0) in the combined endpoint of stroke (hemorrhagic, ischemic or of unspecified type) and systemic embolism, in subjects with AF and at least one additional risk factor for stroke
|
|
E.2.2 | Secondary objectives of the trial |
The key secondary objectives are to determine, in subjects with AF and at least 1 additional risk factor for stroke, if apixaban is superior to warfarin (INR target range 2.0 - 3.0) for, • the combined endpoint of stroke (hemorrhagic, ischemic or of unspecified type) and systemic embolism • major bleeding (ISTH) • all-cause death * To compare, in subjects with AF and at least 1 additional risk factor for stroke, apixaban and warfarin with respect to the composite endpoint of stroke (ischemic, hemorrhagic, or of unspecified type) - systemic embolism and major bleeding, in warfarin naive subjects − systemic embolism and major bleeding − systemic embolism and all cause death − systemic embolism, major bleeding and all cause death − systemic embolism, myocardial infarction and all cause death • To assess the safety of apixaban in subjects with AF and at least 1 additional riskfactor for stroke.
|
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The results of the biomarker sub-study maybe used to help identify high-risk patient chararcteristics and preferred management strategies. The aims of the biomarker sub-study are to evaluate the clinical effects of apixaban within different subgroups base on the level of biochemical markers of myocardial damage, myocardial function, renal function, inflammation, platelet and coagulation activation and metabolism at entry and to evaluate the changes in a subset of these markers over time by the disease process and the influence of drug treatment. |
|
E.3 | Principal inclusion criteria |
For entry into the study, the following criteria MUST be met. 1) Age >= 18 years 2) In atrial fibrillation or atrial flutter not due to a reversible cause and documented by ECG at the time of enrollment. OR If not in atrial fibrillation/flutter at the time of enrollment, must have atrial fibrillation/flutter documented on two separate occasions not due to a reversible cause at least 2 weeks apart in the 12 months prior to enrollment. Atrial fibrillation/flutter may be documented by ECG, or as an episode lasting at least one minute on a rhythm strip or Holter recording or intercardiac electrogram (from an implanted pacemaker or defibrillator). 3) One or more of the following risk factor(s) for stroke: a) Age 75 years or older b) Prior stroke, TIA or systemic embolus c) Either symptomatic congestive heart failure within 3 months or left ventricular dysfunction with an LV ejection fraction (LVEF) =< 40% by echocardiography, radionuclide study or contrast angiography d) Diabetes mellitus e) Hypertension requiring pharmacological treatment 4) Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the treatment period of the study or for 2 weeks after the last dose of study medication, whichever is longer, in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea >= 12 consecutive months; or women on hormone replacement therapy [HRT] with documented serum follicle stimulating hormone [FSH] level > 35 mIU/mL). Even women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or arepracticing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 48 hours prior to the start of investigational product. 5) All subjects must provide signed written informed consent. |
|
E.4 | Principal exclusion criteria |
1) Atrial fibrillation or flutter due to reversible causes (e.g. thyrotoxicosis, pericarditis) 2) Clinically significant (moderate or severe) mitral stenosis 3) Increased bleeding risk that is believed to be a contraindication to oral anticoagulation (e.g. previous intracranial hemorrhage) 4) Conditions other than atrial fibrillation that require chronic anticoagulation (e.g. prosthetic mechanical heart valve) 5) Persistent, uncontrolled hypertension (systolic BP > 180 mm Hg, or diastolic BP > 100 mm Hg) 6) Active infective endocarditis 7) Planned major surgery 8) Planned atrial fibrillation or flutter ablation procedure 9) Use of an unapproved, investigational drug or device within the past 30 days 10) Required treatment with aspirin > 165 mg/day 11) Simultaneous treatment with both aspirin and a thienopyridine (e.g., clopidogrel, ticlopidine) 12) Severe comorbid condition with life expectancy of =< 1 year 13) Active alcohol or drug abuse, or psychosocial reasons that make study participation impractical 14) Recent ischemic stroke (within 7 days) 15) Severe renal insufficiency (serum creatinine > 2.5 mg/dL or a calculated creatinine clearance < 25 mL/min) 16) ALT or AST > 2X ULN or a Total Bilirubin >= 1.5X ULN (unless an alternative causative factor [e.g., Gilbert’s syndrome] is identified) 17) Platelet count =< 100,000/ mm3 18) Hemoglobin < 9 g/dL 19) Inability to comply with INR monitoring 20) Prior randomization into an apixaban clinical study 21) Prisoners or subjects who are involuntarily incarcerated 22) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness 23) Women of child bearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy: a) WOCBP using a prohibited contraceptive method b) WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea >= 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. Even women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of child bearing potential c) Women who are pregnant or breastfeeding d) Women with a positive pregnancy test on enrollment or prior to administration of investigational product. Eligibility criteria for this study have been carefully considered to ensure the safety of the study subjects and to ensure that the results of the study can be used. It is imperative that subjects fully meet all eligibility criteria.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint will be the time to first occurrence of confirmed stroke (ischemic, hemorrhagic, or of type uncertain) or systemic embolism.
Secondary Efficacy Endpoints The secondary efficacy endpoints will be time to first occurrence of confirmed: • ischemic stroke or stroke of unspecified type • hemorrhagic stroke • systemic embolism • all cause death • composite of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, major bleeding • composite of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, all cause death • composite of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, major bleeding, all cause death • composite of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism, myocardial infarction, all cause death • composite of stroke (ischemic, hemorrhagic, or of unspecified type), systemic embolism and major bleeding in warfarin naive subjects
All efficacy outcomes will be adjudicated by the CEC.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 315 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 1 |
E.8.9.2 | In all countries concerned by the trial days | 0 |